The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.

Helen  Mackay

Honoraria - AstraZeneca

Travel, Accommodations, Expenses - AstraZeneca

Bj  Rimel

Honoraria - Genentech

Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Tesaro

David  Bender

No Relationships to Disclose